W. Jahnke

Nature reviews. Drug discovery · 2016

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from W. Jahnke's perspective

Ordered by how strongly the researchers W. Jahnke trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Ligand efficiency: a useful metric for lead selection. (Drug Discovery Today)
  2. A 'rule of three' for fragment-based lead discovery?
  3. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. (Cancer Discovery)
  4. An inhibitor of Bcl-2 family proteins induces regression of solid tumours (Nature)
  5. Crystal structure of the human β2 adrenergic G-protein-coupled receptor
  6. The role of ligand efficiency metrics in drug discovery
  7. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets (Nature Medicine)
  8. Molecular Interaction Studies Using Microscale Thermophoresis (Assay and drug development technologies)
  9. Vemurafenib: the first drug approved for BRAF-mutant cancer (Nature reviews. Drug discovery)
  10. Structure of a β1-adrenergic G protein-coupled receptor (Nature)

Their papers